Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Phase 1 | Participants with moderate-to-severe Psoriasis (PsO) in Japan who have been recruited based on eligibility criteria | ||
| Phase 2 | Self-reported moderate-to-severe Psoriasis (PsO) participants in Japan |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute | Within 60 minutes of survey/interview | |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex | At Baseline | |
| Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age | At Baseline | |
| Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis | At Baseline | |
| Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO | At Baseline | |
| Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO | At Baseline | |
| Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment | At Baseline | |
| Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence | At Baseline | |
| Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status | At Baseline | |
| Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
A total of 10 participants, diagnosed as moderate-to-severe Psoriasis (PsO) by a clinician were included in the Phase 1 qualitative interview
A total of 200 participants, self-reported as moderate-to-severe PsO, were included in the Phase 2 online survey
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Morrisville | North Carolina | 27560 | United States |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| Investigator Inquiry Form | View source |
| FDA Safety Alerts and Recalls |
Not provided
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| At Baseline |
| Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments | At Baseline |
| Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO | At Baseline |
| Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education | At Baseline |
| Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis | At Baseline |
| Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity | At Baseline |
| Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO | At Baseline |
| Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment | At Baseline |
| Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO | At Baseline |
| Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest | At Baseline |
| Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income | At Baseline |